WEKO3
アイテム
A novel anti-podoplanin antibody NZ-16 has the potential as a radioimmunotherapy agent for solid tumors
https://repo.qst.go.jp/records/80656
https://repo.qst.go.jp/records/806569337552f-0d40-4004-90b1-81e3c518b04b
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2020-09-17 | |||||
| タイトル | ||||||
| タイトル | A novel anti-podoplanin antibody NZ-16 has the potential as a radioimmunotherapy agent for solid tumors | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Sudo, Hitomi
× Sudo, Hitomi× Tsuji, Atsushi× Sugyo, Aya× Fujiwara, Kentaro× Mika Kaneko× Yukinari Kato× Higashi, Tatsuya× Sudo, Hitomi× Tsuji, Atsushi× Sugyo, Aya× Fujiwara, Kentaro× Higashi, Tatsuya |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Podoplanin (PDPN) is a glycoprotein that is highly expressed in malignant mesothelioma. We previously showed an anti-PDPN antibody NZ-12 has the potential as a new therapeutic agent for malignant mesothelioma. Here, we developed a novel anti-PDPN antibody NZ-16 having a different constant region from NZ-12. The in vitro and in vivo properties of radiolabeled NZ-16 and the antitumor effects were evaluated in mesothelioma and glioblastoma xenograft mouse models. In vitro assays showed radiolabeled NZ-16 has a higher affinity to PDPN-expressing cells H226 mesothelioma cells and LN319 glioblastoma cells than radiolabeled NZ-12. In vivo biodistribution studies showed high uptake of radiolabeled NZ-16 in H226 and LN319 tumors. Radioimmunotherapy (RIT) with radiolabeled NZ-16 significantly suppressed tumor volumes without obvious adverse events such as body weight loss in both models. The antitumor efficacy of radiolabeled NZ-16 was higher than that of NZ-12. Our findings suggest that RIT with radiolabeled NZ-16 has the potential as a superior therapeutic option for PDPN-expressing tumors. | |||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 第79回日本癌学会学術総会 | |||||
| 発表年月日 | ||||||
| 日付 | 2020-10-01 | |||||
| 日付タイプ | Issued | |||||
